Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessing differences in epigenetic aging markers between sexual or gender minority and straight cisgender adults using the Coronary Artery Risk Development in Young Adults cohort.

Social science & medicine (1982)·2026

Same author

Real-world incidence of cancer therapy-related cardiac dysfunction in a large, diverse, and contemporary cohort.

ESC heart failure·2026

Same author

Electronic Nudges to Increase Influenza Vaccination in Immunosuppressed Adults Across the Age Spectrum: A Pooled Analysis of Two Nationwide Randomized Trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Nudges for Guideline-Directed Medical Therapy in Chronic Kidney Disease: Long-Term Follow-Up of the NUDGE-CKD Trial.

Journal of the American College of Cardiology·2026

Same author

Clinical risk prediction models for worsening heart failure events and all-cause mortality in adults with mild-to-moderate chronic kidney disease.

ESC heart failure·2026

Same author

Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial.

European heart journal open·2026

Same journal

Aortic Valve Replacement in Women of Reproductive Age.

Journal of the American College of Cardiology·2026

Same journal

Sudden Death in Cardio-Kidney-Metabolic Patients: Insights From FINE-HEART.

Journal of the American College of Cardiology·2026

Same journal

Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.

Journal of the American College of Cardiology·2026

Same journal

Reframing Cardiometabolic Risk and Frailty Through Sarcopenic Obesity.

Journal of the American College of Cardiology·2026

Same journal

Imaging-Derived Sarcopenic Obesity and Cardiovascular Outcomes: Insights Into Heart Failure Risk and Muscle Biology.

Journal of the American College of Cardiology·2026

Same journal

The Measure of a Leader: Lessons in Leadership From Eugene Braunwald.

Journal of the American College of Cardiology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2025

In Silico Clinical Trials for Cardiovascular Disease

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Artificial Intelligence in Cardiovascular Clinical Trials.

Jonathan W Cunningham¹, William T Abraham², Ankeet S Bhatt³

¹Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Journal of the American College of Cardiology

|November 6, 2024

Summary

This summary is machine-generated.

Artificial intelligence (AI) can enhance cardiovascular clinical trials by automating processes and improving efficiency. However, careful integration is crucial to mitigate risks like bias and privacy concerns, ensuring trial validity.

Keywords:

artificial intelligence automated large language model randomized

More Related Videos

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

Related Experiment Videos

Last Updated: Jun 8, 2025

In Silico Clinical Trials for Cardiovascular Disease

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening

Published on: April 15, 2017

Area of Science:

Cardiovascular medicine
Clinical trial methodology
Artificial intelligence in healthcare

Background:

Randomized clinical trials are essential for cardiovascular therapy evaluation but face challenges with cost, duration, and diversity.
Artificial intelligence (AI) presents opportunities to optimize clinical trial processes.

Purpose of the Study:

To review the potential applications of AI across the entire lifecycle of cardiovascular clinical trials.
To identify the risks and challenges associated with integrating AI in clinical trials.
To discuss the evolving frameworks for evaluating AI tools in medical research.

Main Methods:

Literature review of AI applications in clinical trial design, patient identification, data collection, outcome ascertainment, imaging interpretation, and result dissemination.
Analysis of potential risks, including data accuracy, algorithmic bias, and patient privacy.
Examination of current regulatory and journal guidelines for AI in research.

Main Results:

AI can streamline various trial stages, from design to data analysis and dissemination.
Significant risks include inaccurate AI outputs, amplification of biases, and privacy breaches.
Regulatory bodies and journals are developing frameworks to address AI in clinical research.

Conclusions:

AI offers transformative potential for cardiovascular clinical trials, improving efficiency and potentially diversity.
Careful, transparent implementation is necessary to manage AI-related risks and maintain trial integrity.
Ongoing development of evaluation frameworks is critical for responsible AI adoption in clinical research.